The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19

  • End date
    Mar 5, 2023
  • participants needed
  • sponsor
    Guy's and St Thomas' NHS Foundation Trust
Updated on 25 March 2021


Up to a third of patients who recovered from SARS coronavirus (SARS-CoV) had a 20% decline in lung function with a long term reduction in exercise capacity and SF-36 health status a year after infection. Similar outcomes are now being reported in COVID-19 patients, with interstitial lung disease (fibrosis) and long term lung function decline being a common feature. Anti-fibrotic monocytes/macrophages are important for the clearance of partially degraded collagen fragments of fibrotic extracellular matrix, in particular fibrillary-type collagen.

MON002 is an autologous monocyte product, cultured in vitro prior to intravenous delivery into patients with post-COVID-19 lung fibrosis.


The MONACO Cell Therapy Study is a prospective, non-randomised, open label study phase I/II clinical trial with a key objective of evaluating safety of MON002 in 5 adults who have a clinical diagnosis of interstitial lung disease (pulmonary fibrosis) after recovery from acute COVID-19 infection. The main objectives of this study are to: (1) to determine the safety profile of MON002 by assessing clinical responses in adults with post-COVID-19 pulmonary fibrosis and (2) to assess its impact on reducing disease morbidity/severity in this population.

Condition Pulmonary Disease, Lung Disease, Pulmonary Fibrosis, Pulmonary Fibrosis, Interstitial lung disease, Lung Disease, COVID19, interstitial lung diseases, lung fibrosis
Treatment MON002
Clinical Study IdentifierNCT04805086
SponsorGuy's and St Thomas' NHS Foundation Trust
Last Modified on25 March 2021


Yes No Not Sure

Inclusion Criteria

Clinical evidence/diagnosis of interstitial lung disease (fibrosis) following COVID-19 infection
Aged at least 18 years
Willing and able to participate in the MONACO Cell Therapy Study
Signed and dated written informed consent

Exclusion Criteria

Subjects who have had other investigational medicinal products within 90 days prior to screening or during the treatment phase
Malignant or premalignant haematological conditions
Serologically positive for antiHIV1,2 HBsAg Anti-HBc Anti-HCVabAnti-HTLV1,2 or syphilis (Treponema palladium)
Concomitant malignancy or history of malignancy within 5 years prior to planned study entry (excluding successfully treated non metastatic basal/squamous cell carcinoma of the skin)
Evidence of significant local or systemic infection
Any uncontrolled medical condition or concurrent disease that could interfere with the study objectives
Clinical diagnosis of interstitial lung disease prior to the COVID-19 infection
Any condition which, in the judgement of the Investigator, would place the subject at undue risk
Female patients of childbearing potential with a positive serum pregnancy test at enrolment
Sexually active Women of Childbearing Potential who do not agree continued abstinence from heterosexual intercourse or to use highly effective methods of birth control for the duration up to 4 weeks post IMP administration. Men who do not agree to use a condom if their partner is of child bearing potential, even if they have had a successful vasectomy after receiving the therapy
Female patients who are breastfeeding
Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow up visit schedule
Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion of the Investigator, may invalidate communication with the Investigator and/or designated study personnel
Patients unable to freely give their informed consent (e.g. individuals under legal guardianship)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note